DK2827862T3 - Formuleringer af bendamustin - Google Patents

Formuleringer af bendamustin Download PDF

Info

Publication number
DK2827862T3
DK2827862T3 DK13764989.3T DK13764989T DK2827862T3 DK 2827862 T3 DK2827862 T3 DK 2827862T3 DK 13764989 T DK13764989 T DK 13764989T DK 2827862 T3 DK2827862 T3 DK 2827862T3
Authority
DK
Denmark
Prior art keywords
bendamustine
formulations
Prior art date
Application number
DK13764989.3T
Other languages
English (en)
Inventor
Srikanth Sundaram
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2827862(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2827862T3 publication Critical patent/DK2827862T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13764989.3T 2012-03-20 2013-03-15 Formuleringer af bendamustin DK2827862T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
PCT/US2013/032289 WO2013142358A1 (en) 2012-03-20 2013-03-15 Formulations of bendamustine

Publications (1)

Publication Number Publication Date
DK2827862T3 true DK2827862T3 (da) 2024-02-12

Family

ID=49212372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13764989.3T DK2827862T3 (da) 2012-03-20 2013-03-15 Formuleringer af bendamustin

Country Status (15)

Country Link
US (19) US9034908B2 (da)
EP (2) EP4360621A3 (da)
JP (8) JP6250628B2 (da)
CN (1) CN104302291A (da)
CA (1) CA2867295C (da)
DK (1) DK2827862T3 (da)
ES (1) ES2972227T3 (da)
FI (1) FI2827862T3 (da)
HR (1) HRP20240056T1 (da)
HU (1) HUE064884T2 (da)
PL (1) PL2827862T3 (da)
PT (1) PT2827862T (da)
RS (1) RS65177B1 (da)
SI (1) SI2827862T1 (da)
WO (1) WO2013142358A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2528602T (lt) 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
HUE062230T2 (hu) 2012-03-20 2023-10-28 Eagle Pharmaceuticals Inc Bendamusztin folyékony készítmények bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak
CA2867295C (en) * 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
MX2016002502A (es) 2013-08-27 2017-02-28 Voudouris Vasilios Composiciones farmaceuticas de bendamustina.
CN105726472B (zh) * 2016-03-25 2019-12-13 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CA3054834A1 (en) * 2019-05-20 2019-11-05 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (da) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
NZ279443A (en) 1994-01-24 1998-04-27 Procter & Gamble Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol
CN1261803A (zh) 1997-07-01 2000-08-02 埃瑟若詹尼克斯公司 抗氧化剂增强对细胞过度增生性疾病的治疗
CA2298823C (en) 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CN101933923A (zh) 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
MX2007006106A (es) 2004-11-22 2007-10-23 Venus Remedies Ltd Formulacion liquida parenteral no acuosa de aceclofenaco.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ATE509634T1 (de) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
CN101500571A (zh) 2006-08-14 2009-08-05 卫材R&D管理有限公司 稳定的冻干制剂
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
MX2011002936A (es) 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
CA2749101A1 (en) 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
NO2792369T3 (da) 2009-02-25 2018-09-15
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
MX2011011109A (es) * 2009-04-28 2011-11-18 Cephalon Inc Formulaciones orales de bendamustina.
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
LT2528602T (lt) * 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012015810A2 (en) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
JP6483442B2 (ja) 2011-12-05 2019-03-13 エックス−ボディ インコーポレイテッド Pdgf受容体ベータ結合ポリペプチド
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
KR101951319B1 (ko) * 2012-02-07 2019-02-22 삼성전자주식회사 가변 초점 렌즈
CN104203235B (zh) * 2012-02-14 2018-11-23 赛多斯有限责任公司 苯达莫司汀的制剂
CA2867295C (en) * 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HUE062230T2 (hu) * 2012-03-20 2023-10-28 Eagle Pharmaceuticals Inc Bendamusztin folyékony készítmények bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak
US9587397B1 (en) * 2015-09-29 2017-03-07 John Milner McCary, SR. Insulating and support assembly
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Also Published As

Publication number Publication date
US20220323584A1 (en) 2022-10-13
SI2827862T1 (sl) 2024-03-29
US20160144034A1 (en) 2016-05-26
US20210106686A1 (en) 2021-04-15
ES2972227T3 (es) 2024-06-11
HUE064884T2 (hu) 2024-04-28
US20200282057A1 (en) 2020-09-10
JP2022130630A (ja) 2022-09-06
JP2015510939A (ja) 2015-04-13
EP4360621A3 (en) 2024-05-22
US20140094496A1 (en) 2014-04-03
US9034908B2 (en) 2015-05-19
US20130253025A1 (en) 2013-09-26
FI2827862T3 (fi) 2024-02-13
CN104302291A (zh) 2015-01-21
PT2827862T (pt) 2024-03-06
EP4360621A2 (en) 2024-05-01
JP2022130629A (ja) 2022-09-06
HRP20240056T1 (hr) 2024-03-29
US20180000938A1 (en) 2018-01-04
JP2022141895A (ja) 2022-09-29
JP2019214592A (ja) 2019-12-19
US20160144035A1 (en) 2016-05-26
US20230285563A1 (en) 2023-09-14
US20160000759A1 (en) 2016-01-07
US20140275196A1 (en) 2014-09-18
EP2827862A4 (en) 2015-11-18
JP2021178846A (ja) 2021-11-18
EP2827862B1 (en) 2023-12-27
US9597399B2 (en) 2017-03-21
JP6570601B2 (ja) 2019-09-04
US9572888B2 (en) 2017-02-21
US9572887B2 (en) 2017-02-21
US20160296621A1 (en) 2016-10-13
US9597398B2 (en) 2017-03-21
US20160296622A1 (en) 2016-10-13
JP6250628B2 (ja) 2017-12-20
JP7133070B2 (ja) 2022-09-07
US20150250766A1 (en) 2015-09-10
JP2018070624A (ja) 2018-05-10
US20200368355A1 (en) 2020-11-26
RS65177B1 (sr) 2024-03-29
US10052385B2 (en) 2018-08-21
CA2867295C (en) 2020-08-11
US9144568B1 (en) 2015-09-29
US20220265829A1 (en) 2022-08-25
US20180369383A1 (en) 2018-12-27
US20190192659A1 (en) 2019-06-27
EP2827862A1 (en) 2015-01-28
US20180185488A1 (en) 2018-07-05
WO2013142358A1 (en) 2013-09-26
JP2024045290A (ja) 2024-04-02
PL2827862T3 (pl) 2024-05-06
US9597397B2 (en) 2017-03-21
CA2867295A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
SMT201700094B (it) Composto di pirazina carbossammide
DK2528602T4 (da) Formuleringer af bendamustin
DK2827862T3 (da) Formuleringer af bendamustin
DK3725778T3 (da) Formuleringer af enzalutamid
CO7061086A2 (es) Combinaciones de compuestos activos
DK3336097T3 (da) Fremstilling af ikke-krystallinsk obeticholsyre
DK2845905T3 (da) Fremstilling af oligosaccharider
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
DK3533792T3 (da) Krystallinske former af en androgenreceptormodulator
DK2968208T3 (da) Behandling af kataplexi
DK2846809T3 (da) Behandling af myelosuppression
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
AR092198A1 (es) Derivados de pirazolopirimidinas
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3450434T3 (da) Deutererede derivater af ruxolitinib
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
DK2919777T3 (da) Transmukosal afgivelse af tocotrienol
DK2880228T3 (da) Stilladsstruktur
BR112014029176A2 (pt) formulações injetáveis de aprepitante
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK2894998T3 (da) Rotation af kegle